Transcenta Continues to Push the Boundary of Cell Culture Productivity by Achieving > 6 g/L PER Day Volumetric Productivity in Continuous Perfusion Platform
News provided by
Share this article
Share this article
SUZHOU and HANGZHOU, China, March 16, 2021 /PRNewswire/ Transcenta, a global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced a major breakthrough in its continuous perfusion cell culture platform by achieving volumetric productivity of > 6 g/L per day while maintaining process and product quality attributes in a state of control for a 4-week culture. This productivity improvement represents a 15-fold increase in drug substance output per year when compared to same cell line in conventional fed-batch process (6 g/L over 14 days). At such high productivity, one 100L or 1,000L single use bioreactor can produce approximately 130 kg or 1.3 metric tons of total drug substanc
Transcenta Holding Limited, a global biotherapeutics company with integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, completed a 105m USD crossover financing.
China Structural Reform Fund led the financing round, participated by new investors including Country Garden Venture Capital, Qatar Investment Authority, and other prominent institutional investors. Existing investors including CCT China Merchants Fund, Lilly Asia Ventures, Teng Yue Partners, Sequoia Capital China and others also participated in this round.
The proceeds from new funding will be used to accelerate ongoing clinical programs and prepare for commercialization.
Led by Dr. Jonathan Y. Zhao, Co-Founder and Chairman, and Dr. Xueming Qian, Co-Founder and CEO, Transcenta is a global biotherapeutics company that fully integrates antibody-based biotherapeutics discovery, development and manufacturing. Transcenta has established global footprint with Discovery and
Transcenta Closes $105 Million in Crossover Financing Published : Wednesday, December 23, 2020, 8:00 am ACROFAN=PRNewswire | mediainquiries@prnewswire.com | SNS
HONG KONG and SUZHOU, China, and HANGZHOU, China, Dec. 23, 2020 /PRNewswire/ Transcenta Holding Limited ( Transcenta ), a global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announces today the completion of a 105 million USD crossover financing. China Structural Reform Fund led the financing round, participated by new investors including Country Garden Venture Capital, Qatar Investment Authority, and other prominent institutional investors. Existing investors including CCT China Merchants Fund, Lilly Asia Ventures, Teng Yue Partners, Sequoia Capital China and others also participated in this round. China Renaissance acted as the lead financial advisor for this transaction, and Bank of China International as joint financi